Sep 26 |
Psilocybin Breakthrough: Study Reveals Potential Application For Body Dysmorphic Disorder
|
Sep 23 |
Compass Pathways to Participate in Cowen Psychedelics and Novel Mechanisms in Neuropsychiatry Summit
|
Sep 13 |
MDMA Therapy For PTSD Faces FDA Delay: Are There Other Ways Forward?
|
Sep 5 |
Shake Up At Lykos Therapeutics After FDA Blocks Ecstasy-Based Treatment, CEO Steps Down
|
Aug 30 |
Compass Therapeutics files $300M mixed securities shelf
|
Aug 28 |
Compass Pathways to participate in three investor conferences in September
|
Aug 25 |
Morgan Stanley Predicts up to 220% Jump for These 2 ‘Strong Buy’ Stocks
|
Aug 23 |
Trials for psychedelic drug candidate for PTSD under scrutiny by FDA - report
|
Aug 19 |
Compass Pathways: Sector-Wide Reality Check Needed Post FDA Lykos MDMA Decision
|
Aug 19 |
More promise for psilocybin in depression but safety remains a concern
|